Overview

Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Etanercept